Quintiles' Lab First in Asia to Earn Prestigious Accreditation from College of American Pathologists

MUMBAI, INDIA – January 16, 2013 – Quintiles today announced that its central laboratory in Mumbai, India, has received accreditation from the College of American Pathologists 15189SM Accreditation Program, becoming the first laboratory in Asia to receive this accreditation and meet the program's rigorous requirements for medical laboratory quality and competence established by the International Organization for Standardization (ISO).

"This accreditation is further evidence of Quintiles' commitment to deliver high quality, harmonized test results to our biopharma customers globally," said Thomas Wollman, senior vice president, Quintiles Global Laboratories. "Quintiles has the world's largest CAP-accredited central laboratory network. We also believe we are the world's best."

CAP 15189SM is a voluntary, non-regulatory accreditation to the ISO 15189:2007 Standard and complements CAP accreditation and other quality systems. The program optimizes processes to improve patient care, strengthens quality standards while reducing institutional errors and risks and controls costs.

CAP Council on Accreditation Chairman Richard Gomez, M.D., FCAP, said: "Our goal with the CAP15189 Accreditation Program is to improve patient care, mitigate risk, optimize performance, and advance quality for medical laboratory testing. The CAP, as it did more than 50 years ago with laboratory accreditation, is breaking new ground with our program devoted to ISO 15189."

Anil Raghavan, managing director, Quintiles India, said: "The accreditation focuses on the continuum of care directly connected with improved patient safety and risk reduction. We are proud to be the first Asia Pacific lab to receive this accreditation, which reflects our commitment to establishing best-in-class practices in the industry."

Quintiles supports global and regional trials in almost every country in the world, with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, and a tightly coordinated network of affiliate laboratories in Argentina and Brazil. All Quintiles laboratories operate with uniform instrumentation and standard operating procedures, delivering high quality, harmonized data.

About Quintiles

Quintiles is the world's leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.